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Objective: Intensity-modulated radiotherapy (IMRT) has
better normal-tissue sparing compared with 3-dimensional conformal radiation (3DCRT). We sought to assess
the impact of radiation technique on pathological and
clinical outcomes in locally advanced non-small cell lung
cancer (LANSCLC) treated with a trimodality strategy.
Methods: Retrospective review of LANSCLC patients
treated from August 2012 to August 2018 at Sheba
Medical Center, Israel. The trimodality strategy consisted
of concomitant chemoradiation to 60 Gray (Gy) followed
by completion surgery. The planning target volume (PTV)
was defined by co-registered PET/CT. Here we compare
the pathological regression, surgical margin status, local
control rates (LC), disease free (DFS) and overall survival
(OS) between 3DCRT and IMRT.
Results: Our cohort consisted of 74 patients with mean
age 62.9 years, male in 51/74 (69%), adenocarcinoma in
46/74 (62.1%), stage 3 in 59/74 (79.7%) and chemotherapy
in 72/74 (97.3%). Radiation mean dose: 59.2 Gy (SD ± 3.8).

Radiation technique : 3DCRT in 51/74 (68.9%), IMRT in
23/74 (31%). Other variables were similar between groups.
Major pathological response (including pathological
complete response or less than 10% residual tumor cells)
was similar: 32/51 (62.7%) in 3DCRT and 15/23 (65.2%)
in IMRT, p=0.83. Pathological complete response (pCR)
rates were similar: 17/51 (33.3%) in 3DCRT and 8/23
(34.8%) in IMRT, p=0.9. Surgical margins were negative in
46/51 (90.1%) in 3DCRT vs. 17/19 (89.4%) in IMRT (p=1.0).
The 2-year LC rates were 81.6% (95% CI 69-89.4%); DFS 58.3%
(95% CI 45.5-69%) and 3-year OS 70% (95% CI57-80%).
Comparing radiation techniques, there were no significant
differences in LC (p=0.94), DFS (p=0.33) and OS (p=0.72).
Conclusion: When used to treat LANSCLC in the neoadjuvant setting, both IMRT and 3DCRT produce comparable
pathological and clinical outcomes.
Advances in knowledge: This study validates the realworld effectiveness of IMRT compared to 3DCRT.
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Introduction
Radiation therapy is frequently used in the treatment of stage
III non-small cell lung cancer (NSCLC), using a range of radiation techniques. In three-dimensional conformal radiotherapy
(3DCRT) several un-modulated fields (typically 3–4) are designed
to deliver dose directed to the targets. With intensity-modulated
radiotherapy (IMRT), optimized modulated radiation fields
(typically 6–12) are designed to deliver the dose to the target. The
shapes and intensities of each radiation field in IMRT are optimized by means of computer algorithms to conform the dose to
the target and to spare the nearby critical structures. Volumetric
modulated arc therapy (VMAT) delivers radiation by rotating
the gantry while the radiation beam remains on, simultaneously
changing rotation speed, shape of the radiation field, and rate
of delivered dose. Both IMRT and VMAT planning techniques
improve target coverage and reduce radiation exposure to adjacent critical organs compared to 3DCRT.1,2

Treatment
Our institutional trimodality approach, as well as chemotherapy
protocols and radiation planning objectives have been previously
described.6 Briefly, positron emission tomography/CT (PET/CT)
imaging for target delineation was used by image registration and
fusion to the planning CT scan. Elective nodal irradiation was not
used. Margins from gross tumor volume (GTV) to clinical target
volume (CTV) was 0.5 cm, and from CTV to planning target
volume (PTV) was 0.5–1 cm. Radiation dose was prescribed to
60 Gy except if limited by organ-at-risk doses, or stopped early
due to patients' side-effects. Tissue heterogeneity corrections
were included in the treatment planning system. Dose calculations were performed using the analytical anisotropic algorithm
(AAA) in the Eclipse (Varian Medical Systems, Palo Alto, CA,
USA) treatment planning system. Radiation in both cohorts had
a planned prescription goal of ≥95% of the treatment dose was
prescribed volumetrically to >95% of the PTV.

Yet, with these advanced technologies, a great deal of concern
has been expressed regarding the potential for interplay-effect
between target motion and collimator motion that may lead to
insufficient tumor irradiation during IMRT and VMAT delivery.
Tumor movement due to respiration introduces another level of
complexity to IMRT treatment planning and delivery, as each
radiation field segment may only cover a portion of the target
volume at any particular time.3 Court et. al found that for most
treatment techniques, these dose deviations averaged out after
several fractions.4 However, prospective, randomized trial results
directly comparing the efficacy and toxicity of 3DCRT vs IMRT
for lung cancer have not yet been published.5

Patients were categorized according to radiation treatment technique: 3DCRT vs IMRT. For the purpose of the analysis, IMRT
and VMAT cases were combined together. Patients who were
treated with a hybrid 3DCRT-IMRT plan were included in the
IMRT cohort. Prior to 2016, our protocols included 3DCRT
techniques except for tumors that were located close to the spine,
in which case IMRT was preferred. Since the middle of 2016,
IMRT has become the standard modality in our department for
locally advanced lung cancer (LANSCLC) patients.

We therefore performed a retrospective study, comparing
3DCRT vs IMRT. Primary endpoints included pathological
response after chemoradiation and the margins of the resected
surgical specimens; secondary endpoints were clinical outcomes
including local control (LC) disease free survival (DFS) and
overall survival (OS). We hypothesized that the two technologies produce the same rates of pathological response and similar
clinical results.
Methods and materials
Retrospective, single institution, case review study. Electronic
medical records were searched for patient and treatment characteristics, after Institutional Review Board approval.
Patients
Inclusion criteria: patients with Stage IIB to IIIB (American
Joint Committee on Cancer seventh Edition) non-small cell
lung cancer (NSCLC), who were treated at Sheba Academic
Medical Center, Israel between August 2012 and August 2018
with concurrent chemotherapy and external beam radiotherapy
(CCRT), followed by surgery. Exclusion criteria were small
cell lung cancer, metastatic disease, and patients who did not
undergo completion surgery. We did include one patient with
solitary brain metastasis that was treated with stereotactic brain
radiosurgery. Information on follow-up was reviewed up to
January 2019.
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Daily image guided radiation therapy (IGRT) using daily kilovoltage imaging (kV/kV) or cone-beam CT (CBCT) was systematically applied to all lung cancer patients in our cohort. The
choice of IGRT was according to physician guidance. For any
patient, if more than 50% of images used were CBCT, it was listed
in the CBCT group, and if less than 50% it was listed in the kV/
kV group.
Chemotherapy was prescribed concurrently with the radiation,
with platinum doublet, at the choice of the medical oncologist.
Standard treatment regimens were:
• Cisplatin (CN) (37.5 milligram/meter square (mg/m2) Day1,
Day8, Day22, Day38) and vinorelbine (12.5 mg/m2 Day1,
Day8, Day22, Day38)
• Carboplatin (CT) at area-under curve (AUC) two with
paclitaxel at 45 mg/m2 both given every week or carboplatin at
AUC 5 with paclitaxel 175 mg/m2 every 3 weeks q3w
• Etoposide (EP) at 100 mg/m2 Day1-3 with cisplatin at 75 mg/
m2 q3w or etoposide 50 mg/m2 Day1-5 with cisplatin 50 mg/
m2 Day1,Day8 q4w
Surgery: A complete anatomical resection with hilar and mediastinal lymph node dissection was performed 6-to-8 weeks
following completion of CCRT. The preferred surgical approach
was a muscle-sparing lateral thoracotomy.
Pathological analysis
Pathological endpoints were tumor-regression and the surgical-margin status.

Br J Radiol;92:20180960
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Pathological response was evaluated on the specimens according
to protocols recommended by the College of American Pathologists, based on the modified tumor regression grading, as
suggested by Junker et al.7 Response was recorded as a dichotomous variable with ‘favorable' or ‘unfavorable' groups. Favorable
pathological response included major tumor regression (MTR),
defined as residual viable tumor estimated to be less than 10% of
suspected area, or complete pathological response (pCR) if there
were no viable tumor cells identified. Unfavorable pathological
response was recorded if there was residual tumor of more than
10%, or no response.
Additionally, a continuous variable was assessed, based on the
average percentage area of residual tumor cells that remained
as a proportion of the treatment-affected region of the excised
lung. A pathological regression score was based on information
from the primary tumor and the excised lymph nodes combined.
Pathologic specimen scoring, performed by two senior pathologists, was blinded to the techniques of radiation.
Clinical outcomes
Local control (LC) and disease free survival (DFS) were determined by radiological follow-up (CT or PET/CT). Patients who
were lost to follow up were censored at the last date of follow up.
Survival status was determined from the national health database. We recorded episodes of acute toxicity (up to 3 months
post-treatment) from the chemoradiation, according to the
Common Terminology Criteria for Adverse Events version 4
(CTCAE v4), as well as acute complications following surgical
resection (3 months post- surgery).
Statistical analysis
Outcomes in the 3DCRT and IMRT groups were compared
using non-parametric tests. We used the two-tailed chi-squared
or Fisher exact test, as needed for dichotomous variables. For
continuous variables that were normally distributed, the T-test or
one-way ANOVA were used. Mann-Whitney or Kruskal-Wallis
tests were used for non-parametric variables. The threshold of
statistical significance was p<0.05. Kaplan-Meier estimation and
log-rank regression, using STATA V.13 (StataCorp LLC) was
used for survival analysis.
Results
Our cohort included 74 patients (Table 1). Mean age was 62.9
years (range 45–79.7); 69% were male. Smoking status was:
current smokers in 64.8% and past smokers in 14.8%. Histology
was adenocarcinoma in 62.1% and squamous cell carcinoma
in 28.3%. Clinical stages were IIB, III and IV in 18.9%, 79.7%
and 1.2% respectively. Chemotherapy comprised CN, CT, EP in
28.4%,58.1% and 9.5% respectively..
Radiation dose: mean 59.2 Gy; (SD ±3.8; range 46–72); 90.5%
of all cases were treated to at least 54 Gy. The technique used
for radiation treatment was 3DCRT in 68.9%, IMRT in 6.7% and
VMAT in 24.3%. Surgery type included: lobectomy, lobectomy
with chest wall resection and pneumonectomy in 70.3%, 12.1
and 17.6% respectively.
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Pathological response: favorable pathological response including
pCR was observed in 48/74 patients (64.9%); unfavorable pathological response was observed in 26/74 patients (35.1%).
The 3DCRT and the IMRT groups were comparable in all variables besides the IGRT (Table 1): in the 3DCRT group the IGRT
was CBCT in 12/51 (23.5%) vs 14/23 (60.9%) in IMRT group (p
< 0.001).
Tumor volumes and dosimetric parameters are presented in
Table 2. The total tumor volume, the primary tumor (gross
target volume, GTV) and the lymph node volumes were similar
between the two groups. The dosimetric parameters including
lung V20 (volume receiving above 20 Gy), mean lung dose and
mean esophageal dose were similar between the treatment techniques. The lung V5 (volume receiving above 5 Gy) was higher in
the IMRT compared to 3DCRT group (53% vs 43.2%, p = 0.024).
The PTV covered by 95% of the prescribed dose was higher in
IMRT vs 3DCRT (97% vs 93.7%, p < 0.01). The mean heart dose
in IMRT and 3DCRT groups was 7.2 Gy and 10.2 Gy respectively (p = 0.53) and the volume of the heart receiving 45 Gy and
above (heart V45) was smaller in IMRT compared to 3DCRT
groups (2.1cc vs 7.5cc, p =0.06). The maximal dose to the spine
was lower in IMRT vs 3DCRT (38.8Gy vs 42.89Gy p<0.005).
Pathological response and radiation technique
(Figure 1)
Favorable pathological response was similar between radiation techniques: for 3DCRT 32/51 (62.7%) and for IMRT 15/23
(65.2%) (p = 0.83). The rate of pCR was also similar for 3DCRT
(17/51,33.3%) and IMRT (8/23,34.8%) (p = 0.9). The average
percentage area of residual tumor cells was also similar between
the radiation techniques: for 3DCRT 16% (SD ±25.5) and for
IMRT 22% (SD ±27.2) (p = 0.36).
Margins were negative in 90.1% (46/51) of patients treated with
3DCRT compared to 89.4% (17/19) with IMRT (p = 1.0).
Clinical outcome and radiation technique
At median follow-up of 3.6 years, the 2-year overall survival for
3DCRT was 82% (95% CI, 68–90%) and for IMRT was 85% (95%
CI, 60–95%) (p = 0.72). 2-year overall LC rates were 81.6% (95%
CI, 69–89.4%), DFS 58.3% (95% CI, 45.5–69%) and 3-year OS
70% (95% CI, 57–80%). Comparing radiation techniques, there
were no significant differences in LC (p = 0.94), DFS (p = 0.33) or
OS (p = 0.72). (Figure 2a,b,c).
DFS differed according to the pathological response. With ‘favorable' pathological response, 2-year DFS was 71.9% (95% CI,
55–83%) compared to 35.3% (95% CI, 17.4–53.8%) in the ‘unfavorable' pathological response group (p = 0.01); HR 2.45 (95%
CI, 1.24–4.8) (Figure 2d).
OS at 2 years was also better if there was a favorable pathological response: 86.3% (95% CI, 72–93.6%) vs 74.8% (95%
CI, 52–87.7%) with an unfavorable pathological response, but
this difference did not reach statistical significance (p = 0.29).
(Figure 2e).
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Table 1. Patients’ characteristics, disease and treatment details
Parameter

N (%)
total 74

3DCRT total 51

IMRT total 23

p value

N (%)

N (%)

62.9 (45–79.7)

63.2 (45–79.7)

62.2 (47.3–75.6)

NS (p = 0.9)

 Male

51 (69%)

38 (74.5%)

13 (56.5%)

NS (p = 0.09)

 Female

23 (31%)

13 (25.5%)

10 (43.6%)

 Current

48 (64.8%)

35 (68.6%)

13 (56.5%)

 Past

11 (14.8%)

8 (15.7%)

3 (13%)

 Never

13 (17.5%)

7 (13.7%)

6 (26.1%)

 Missing

2 (2.7%)

1 (1.9%)

1 (4.3%)

 Squamous cell carcinoma

21 (28.3%)

17 (33.3%)

4 (17.4%)

 Adenocarcinoma

46 (62.1%)

30 (58.8%)

16 (69.5%)

 Other

7 (9.4%)

4 (7.8%)

3 (13%)

 II

14 (18.9%)

10 (19.6%)

4 (17.4%)

 III

59 (79.7%)

40 (78.4%)

19 (82.6%)

 IV

1 (1.2%)

1 (2%)

0 (0%)

 CN

21 (28.4%)

19 (37.2%)

2 (8.7%)

 CT

43 (58.1%)

27 (53%)

16 (69.6%)

 EP

7 (9.5%)

3 (5.9%)

4 (17.4%)

 Other

2 (2.7)

1 (2%)

1 (4.3%)

 Not received

1 (1.4%)

1 (1.9%)

0 (0%)

 Lobectomy

52 (70.3%)

35 (68.6%)

17 (74%)

 Chest wall resection

9 (12.1%)

6 (11.7%)

3 (13%)

 Pneumonectomy

13 (17.6%)

10 (19.6%)

3 (13%)

 Complete response

25 (33.8%)

17 (33.3%)

8 (32%)

 <10% residual

23 (31%)

16 (31.4%)

7 (30.5%)

 >10% residual

21 (28.3%)

14 (27.5%)

7 (33.4%)

 No response

5 (6.7%)

4 (7.8%)

1 (20%)

17.8% (SD ± 26)

16% (SD ± 25.5)

22% (SD ± 27.2)

NS (p = 0.36)

 Negative

67 (90.5%)

46 (90.2%)

20 (87%)

NS (p = 1)

 Positive

6 (8.1%)

5 (9.8%)

2 (8.7%)

 Missing

1 (1.4%)

0 (0%)

1 (4.3%)

Age
 Mean years, (range)
Gender

Smoking status
NS (p = 0.40)

Histology
NS (p = 0.33)

Stage
NS(p = 0.79)

Chemotherapy
p = 0.15

Surgery
NS (p = 0.82)

Pathological response
NS (p = 0.83)

Average percent of pathological
residual tumor cells
 (mean ± SD)
Margin

(Continued)
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Table 1 (Continued)
IGRT
 kV/kV

47 (63.5%)

39 (76.5%)

8 (34.8%)

 CBCT

26 (35.1%)

12 (23.5%)

14 (60.9%)

 Missing

1 (1.4%)

0 (0%)

1 (4.3%)

p < 0.001

3DCRT. 3 dimensional conformal radiation; IMRT, intensity modulated radiation therapy; SD, standard deviation; NS, not significant; CN,
cisplatin-vinorelbine; CT, carboplatin-paclitaxel; EP, etoposide-cisplatin; IGRT, image guided radiation therapy; Kv/Kv, kilovoltage imaging;
CBCT, cone beam CT.

Toxicities and complications
Grade 2 acute esophageal toxicity from radiation was lower with
IMRT (32% compared to 37% with 3DCRT, p = 0.66). Grade 4
esophagitis was recorded in 4% in 3DCRT vs 0% in IMRT (p =
0.53). Respiratory side-effects were recorded in 8% 3DCRT and
5% IMRT (p = 0.6) (Supplementary Table 1).

Acute complications from surgery were: respiratory 36% in both
modalities. Chest wall necrosis occurred in three cases and broncho-pleural fistula in five cases (all in the 3DCRT group). Grade
5 surgical complications occurred in two patients in the 3DCRT
group (2.7% of total 74 patients). Both of them underwent right
pneumonectomy (Supplementary Table 1).

Table 2. Comparison of Tumor Volumes and Dosimetric parameters between 3DCRT and IMRT

Total tumor volume (cc)
Gross tumor volume GTV (cc)
Lymph node volume (cc)
Prescribed dose (Gy)
PTV D95 (%)
Lung V20 (%)
Mean lung dose (Gy)
Lung V5 (%)
Heart 45 (cc)
Mean heart dose (Gy)
Mean esophageal dose (Gy)
Spine max dose (Gy)

Mean ± SD
(Median, range)

P value

3DCRT

169.6 ± 124.7 (152, 16–168)

0.14

IMRT

133 ± 122.2 (77–432)

3DCRT

135.2 ± 134.8 (99, 0–685)

IMRT

99.8 ± 115.5 (40, 2–418)

3DCRT

34.3 ± 42 (25, 0-182)

IMRT

33.2 ± 34.7 (24.5, 0–145)

3DCRT

58.9 ± 3.4 (60,48–66)

IMRT

60 ± 4.7 (60, 46.2–72)

3DCRT

93.7 ± 4 (95, 78–99)

IMRT

97 ± 3.4 (98.6, 88.5–100)

3DCRT

23.4 ± 6.7 (24, 4–37)

IMRT

24 ± 5.2 (24.4, 6.6–32.5)

3DCRT

13.7 ± 3.70 (14, 3-28)

IMRT

14.17 ± 2.88 (14, 4–17.4)

3DCRT

43.4 ± 17 (38, 10-81)

IMRT

53.5 ± 11.5 (56.2, 13–66)

3DCRT

7.5 ± 11.1 (2.3, 0–47)

IMRT

2.1 ± 3.6 (0.5, 0–12.6)

3DCRT

10.24 ± 10.18 (6.15, 0–34)

IMRT

7.2.18 (5.5, 0–19.5)

3DCRT

19.96 ± 9.63 (20, 0-47)

IMRT

20.15 ± 5.95 (20.9, 8.4–29.7)

3DCRT

42.89 ± 10.36 (47.6, 4.4–54)

IMRT

38.8 ± 8.10 (40.5,21–49.3)

0.26
0.6
p = 0.31
<0.01
0.75
0.613
0.02
0.06
0.53
0.86
0.005

3DCRT, 3 dimensional conformal radiation; IMRT, intensity modulated radiation therapy; Gy, radiation units in Gray; PTV. planning target volume;
D95, volume covered by 95% of the dose; LungV20, volume receiving above 20 Gy; LungV5, volume receiving above 5 Gy; Heart 45, heart volume
receiving dose above 45 Gy.
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Figure 1. The pathological response by radiation treatment
technique.

group, with doubling of the 2-year DFS from 35.3 to 71.9% (HR
2.45 p = 0.01).
The feasibility of NSCLC treatment with chemoradiation to high
dose (60 Gy) in the neoadjuvant setting has been reported. The
RTOG 0229 Phase II trial prescribed “full-dose” concurrent
chemoradiation (i.e. 60 Gy) followed by resection. Mediastinal
pathological clearance was observed in 63% of patients, similar
to our finding of 64.8% major tumor regression. There was a 14%
(5/37) incidence of grade 3 postoperative pulmonary complications and only one postoperative grade 5 adverse event (3%),
comparable to our surgical complication rates. Similarly, they
reported a 2-year OS of 75% for those who achieved nodal clearance vs 52% for those with residual nodal disease.10

Discussion
Compared to 3DCRT, IMRT offers improved target coverage
and reduced doses to organ at-risk by using complex modulated radiation beams. However, in lung cancer therapy there has
been concern regarding the ‘interplay effect’ that may potentially
reduce the actual dose delivered to the tumor.
In this study we found that for NSCLC, 3DCRT and IMRT
techniques resulted in similar pathologic response, negative
margins, local control, disease free and overall survival. This data
adds support to the effectiveness of IMRT compared to 3DCRT
modalities in treating LANSCLC.
In a dosimetric study, Bortfeld et al found that for a typical
treatment with 30 fractions, the standard deviation of the delivered dose is generally within 1% of the expected value for dose
delivery if one assumes a typical motion amplitude of 5 mm (1 cm
peak-to-peak) due to averaging of the dose in fractionated IMRT
planning. This is the same as for treatments with conventional
static beams.8 Therefore, the final dose delivered to the target and
normal tissue is expected to be similar to that for conventional
radiotherapy delivered without intensity modulation, and the
additional effects specific to the IMRT delivery technique seem
to be relatively small.
To our knowledge this study is the first report of comparison between these techniques, using pathologic regression
scoring after 60 Gy chemoradiation to LANSCLC, thus, further
supporting the previously reported dosimetric studies.
In a study by Pataer et al, the percentage of residual viable tumor
cells and surgical pathologic stage were associated with OS. Longterm OS and DFS were significantly prolonged in patients who
had ≤10% viable tumor cells (favorable response) compared with
patients with >10% viable tumor cells (unfavorable response);
with 5-year OS 85% vs 40% (p < 0.0001) and 5-year DFS 78
vs 35% (p < 0.001), making this cut-point a clinically relevant
endpoint to measure.9 Our study also confirmed a statistically
significant increase in DFS in the favorable pathologic response
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In our study we observed lower rates of serious surgical complications in IMRT vs 3DCRT: grade 4 complications in 6% with
3DCRT compared to0% in IMRT and grade 5 complications in
2 out of 51 patients (4%) in 3DCRT compared to 0% in IMRT.
This may be explained by the improved conformity and homogeneity of the IMRT planning technique compared to 3DCRT but
requires validation in a larger cohort.
Moreover, we found reduced rates of esophagitis as well as respiratory toxicity in the IMRT group. In a retrospective study by
Yom et al, reduced grade ≥3 pneumonitis was seen in IMRT
compared to 3DCRT (8% vs 32%).11 The RTOG 0617, a prospective, randomized phase III trial, compared definitive chemoradiation to 60 Gy vs 74 Gy. They observed that the decline in
quality-of-life was significantly reduced with the use of IMRT,
suggesting that improved radiation technique may help enhance
the therapeutic window for patients with lung cancer.12 In a
secondary analysis of this pivotal trial, 2-year OS, LC and PFS
were compared between IMRT and 3DCRT, and, as concluded
in this study, found to be similar between techniques. Furthermore, Chun et al also reported reduced pneumonitis with IMRT
compared with 3DCRT (7.9% vs 3.5%, p = 0.04) and lower heart
doses (p < 0.05). In fact, their study suggested that the volume
of heart receiving high-dose was associated with OS (p < 0.05),
further supporting routine use of IMRT for locally advanced
NSCLC.13 In our analysis the volume of the heart receiving highdose was also lower in IMRT than in 3DCRT (p = 0.06).
Two population-based studies have shown IMRT to be associated with significantly decreased incidence of pulmonary
toxicity, reduced esophagitis rate and fewer placements of percutaneous gastric feeding tubes.14,15 Reduced incidence of esophagitis may also be the result of dose de-escalation to the lymph
nodes. According to Van de Bosch et al, lymph node control may
be achieved at lower radiation doses than needed for the primary
tumor.16
Comparative effectiveness between 3DCRT and IMRT for stage
III NSCLC has been assessed in population-based studies, with
the two techniques found to be similar in local control and
survival in the definitive setting (without completion surgery).
Shirvani et al found that based on the SEER-Medicare database,
IMRT was associated with similar oncologic outcomes to those
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Figure 2. Kaplan Meier survival estimates of (a) Local Control (b) Disease Free Survival and (c) Overall Survival according to treatment technique, and disease free survival (d) and overall survival (e) according to pathological regression. 3DCRT, three dimensional conformal radiation therapy; IMRT intensity modulated radiation therapy.

of 3DCRT15 and even improved overall survival compared to
3DCRT in cases of large tumors.14
In our study the IGRT was correlated to the technique: daily
CBCT was performed in 14/22 (63.6%) of the IMRT group
compared to only 23.5% with 3DCRT. Volumetric imaging, in
particular, CBCT offers more precise localization of soft tissue
targets and critical organs which reduces setup uncertainty and
permits the use of smaller volumes and complex planning. This
has real implications for radiotherapy's therapeutic ratio. Bissonnette et al showed that using IGRT, high geometric accuracy is
achievable for NSCLC patients, potentially leading to reduced
PTV margins.17 Furthermore, in a retrospective trial, Kilburn
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et al demonstrated a substantial local control increase of 16%
for patients treated with IGRT using daily kV/kV or CBCT
compared to weekly MV portal imaging.18
Limitations of this study include the retrospective design and
single-center cohort, making generalization of the results to other
cancer centers limited. However, the use of uniform methods
of radiotherapy planning and blinded pathologic reporting
strengthen our findings.
Since prospective randomized trials comparing these techniques
are unlikely to be conducted, this study adds evidence for the
comparative effectiveness of IMRT in lung radiation therapy
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based on NSCLC pathological specimens that were excised after
60 Gy chemoradiation.

according to pathological specimens, in the trimodality treatment strategy.

In conclusion, for the first time we have demonstrated the
comparative effectiveness of IMRT and 3DCRT for LANSCLC,
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